Propanc Shares Data on Lead Product Treating Cancer

Propanc Biopharma (OTCQB:PPCH) announced new insights about how cancer stem cells can resist standard treatments, become more aggressive and spread rapidly.
As quoted in the press release:

Published in Oncogene, by researchers from the Bellvitge Biomedical Research Institute south of Barcelona, Spain, the findings have significant implications for Propanc Biopharma’s lead product PRP, which reprograms CSCs so that they are no longer malignant and a threat to the patient. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
One of the authors from the study, Dr Miguel Ăngel Pujana, describes why tumors adapt to and resist certain therapies, like mTOR inhibitors, a treatment used in advanced stages of breast cancer. He links mTOR inhibition with increased expression of certain genes, like EVI1, which contributes to epithelial to mesenchymal transition (EMT), a key process by which cancer cells become stem cell-like, motile and invasive, seeding new tumors. Dr Miguel concludes, “Tumor cells are able to adapt to treatment through a phenotype (character) shift that makes them more aggressive and sustains their metastatic potential.” Data from hundreds of cell lines expand on the concept that CSCs are frequently the source of therapy resistance and metastasis, the main cause of patient death from cancer.
“When administering PRP to a patient, we are essentially reprogramming CSC gene expression, pushing these cells back to a normal, less malignant state, so they die naturally,” said Dr Kenyon, Propanc’s Chief Scientific Officer. “Reversing the EMT process is a key feature of PRP and is fast becoming a credible solution to controlling CSCs, which are responsible for cancer spreading, or metastasis, the main cause of patient death from cancer.”

Click here to read the full press release.